(Q34364743)

1 August 2017

1 reference

title

Cytoreductive surgery for ovarian cancer. (English)

1 reference

1 August 2017

1 reference

Randall TC

1

1 reference

1 August 2017

Rubin SC

series ordinal

2

1 reference

1 August 2017

publication date

1 August 2001

1 reference

Surgical Clinics of North America

1 August 2017

published in

1 reference

1 August 2017

volume

81

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

871-883

1 reference

Debulking surgery: Does it increase the quality of survival?

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Stage IV ovarian cancer: impact of surgical debulking

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Stage III epithelial ovarian cancer: the role of maximal surgical reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

The impact of subspecialty training on the management of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Epithelial ovarian carcinoma: principles of primary surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Effect of surgical debulking on survival in stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Secondary cytoreductive surgery for recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Evaluation of treatment and survival after positive second-look laparotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Intervention debulking surgery in advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Neoadjuvant chemotherapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Secondary cytoreduction for ovarian cancer following cisplatin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Management of epithelial ovarian tumors of low malignant potential

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

The behavior of serous tumors of low malignant potential: are they ever malignant?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970171-7

7 January 2021

10.1016/S0039-6109(05)70171-7

Identifiers

DOI

1 reference

1 August 2017

1 reference